You are here

  • Home
  • Archive
  • Volume 81, Issue 9
  • Response to: ‘Exaggerated neutrophil extracellular trap formation in Kawasaki disease: a key phenomenon behind the outbreak in western countries?’ by Yamashita et al

Article Text

Article menu
Download PDFPDF
Correspondence response
Response to: ‘Exaggerated neutrophil extracellular trap formation in Kawasaki disease: a key phenomenon behind the outbreak in western countries?’ by Yamashita et al
  1. Marie Pouletty1,2,
  2. Glory Dingulu1,
  3. Naim Ouldali1,2,3,
  4. Olivier Corseri1,
  5. Camille Ducrocq1,2,
  6. Ulrich Meinzer1,2,4,5,
  7. Albert Faye1,2,3,
  8. Caroline Galeotti6,
  9. Isabelle Melki1,7,8
  10. Great Paris Region (GPR) Kawa-COVID-19 consortium
    1. 1 General Paediatrics, Department of Infectious Disease and Internal Medicine, Reference centre for Rheumatic, AutoImmune and Systemic diseases in children (RAISE), Robert Debré University Hospital, AP-HP, Paris, France
    2. 2 Université de Paris, UFR de Médecine Paris Nord, 75010 Paris, France
    3. 3 INSERM UMR 1123, ECEVE, Paris, France
    4. 4 Center for Research on Inflammation, UMR1149, INSERM, Paris, France
    5. 5 Biology and Genetics of Bacterial Cell Wall Unit, Pasteur Institute, Paris, France
    6. 6 Department of Pediatric Rheumatology, Reference centre for Autoinflammatory diseases and amyloidosis (CEREMAIA), Hôpital Bicêtre, AP-HP, Le Kremlin-Bicêtre, France
    7. 7 Paediatric Hematology-Immunology and Rheumatology Department, Reference centre for Rheumatic, AutoImmune and Systemic diseases in children (RAISE), Paris, France, Necker-Enfants-Malades University Hospital, AP-HP, Paris, France
    8. 8 Laboratory of Neurogenetics and Neuroinflammation, Imagine Institute, Paris, France
    1. Correspondence to Isabelle Melki, General Paediatrics, Infectious Diseases and Internal Medicine, Hopital Universitaire Robert Debre, Paris, F-75019, France; isabelle.melki{at}aphp.fr

    https://doi.org/10.1136/annrheumdis-2020-218644

    Statistics from Altmetric.com

      Request Permissions

      If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

      We read with interest the correspondence from Mizugishi et al.1 The pathophysiology of Kawasaki disease (KD) and more recently Kawasaki-like paediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 (PIMS-TS) or Kawa-COVID-19 remains largely unknown, even if the infectious trigger by SARS-CoV-2 in the prior weeks seems to be a key feature.2 Furthermore, it is still uncertain whether Kawasaki-like PIMS-TS can be considered as the same entity as KD or if it should be individualised as a novel distinct condition, as it may have been suggested with several significant clinical and biological differences between classical KD and Kawa-COVID-19.3

      Mizugishi et al 1 speculate that KD and Kawa-COVID-19 share a common pathophysiology through excessive neutrophil extracellular trap (NET) formation. Similar to Yoshida et al,4 Mizugishi et al 1 showed increased NET formation in KD patients sera. Through a KD mouse model, the authors describe that severe vasculitis (in the aorta and coronary arteries) was associated with infiltrative neutrophils. Those neutrophils were primed to produce NETs through the PAD4 pathway and seemed to produce a specific type of NET formation (enriched in citrullinated histones). Excessive NET formation was also described in sera of adult COVID-19 patients with endothelial injuries. Kawa-COVID-19 could represent a severe form of KD triggered by an exaggerated NET formation induced by SARS-CoV-2.

      NETs are an important first-line defence mechanism against bacterial, viral, fungal and parasitic infections, but they have been also suspected to play a role in autoimmune diseases such as systemic lupus erythematosus (SLE) or antineutrophil cytoplasmic antibodies-associated vasculitis (AAV) for example.5 Van Dam et al 5 showed that NET formation is involved in the pathophysiology of two clinically and pathologically distinct forms …

      View Full Text

      Footnotes

      • Handling editor Josef S Smolen

      • Collaborators Great Paris Region (GPR) Kawa-COVID-19 consortium: Charlotte Borocco, MD(Department of Pediatric Rheumatology, Hôpital Bicêtre, AP-HP, Reference centre for Autoinflammatory diseases and amyloidosis (CEREMAIA), Le Kremlin-Bicêtre, France, Department of Immunology, Robert Debré University Hospital, AP-HP, Paris, France), Marion Caseris MD (General Paediatrics, Department of Infectious Disease and Internal Medicine, Robert Debré University Hospital, AP-HP, Paris, France, Reference centre for Rheumatic, AutoImmune and Systemic diseases in children (RAISE), Paris, France, Department of Microbiology, Robert Debré University Hospital, AP-HP, Paris, France), Johanna Lokmer MD (Cardiopaediatric Unit, Robert Debré University Hospital, AP-HP, Paris, France), Cherine Benzouid MD (Cardiopaediatric Unit, Robert Debré University Hospital, AP-HP, Paris, France), Constance Beyler MD (Cardiopaediatric Unit, Robert Debré University Hospital, AP-HP, Paris, France), Romain Basmaci MD, PhD (Departments of General Paediatrics and Paediatric Emergency, Louis-Mourier Hospital, AP-HP, Colombes, France, Infection-Antimicrobials-Modelling-Evolution IAME, INSERM, UMR-1137, Université de Paris, 75018, Paris, France), Noémie Lachaume MD (Departments of General Paediatrics and Paediatric Emergency, Louis-Mourier Hospital, AP-HP, Colombes, France, Infection-Antimicrobials-Modelling-Evolution IAME, INSERM, UMR-1137, Université de Paris, 75018, Paris, France), Philippe Bensaid MD (Department of General Paediatrics, Victor Dupouy Hospital, Argenteuil, France), Samia Pichard MD (Department of General Paediatrics, Victor Dupouy Hospital, Argenteuil, France), Hanane Kouider MD (Department of General Paediatrics, René Dubos, Pontoise Hospital, France), Guillaume Morelle MD (Department of General Paediatrics Hôpital Bicêtre, AP-HP, Kremlin-Bicêtre, France), Irina Craiu MD (Paediatric emergency Department, Hôpital Bicêtre, AP-HP, Kremlin-Bicêtre, France), Corinne Pondarre MD, PhD (Sickle cell disease referal center, Centre hospitalier Intercommunal de Créteil, INSERM U955, Paris XII University), Arielle Maroni MD (Université de Paris, UFR de Médecine Paris Nord, 75010 Paris, France, Paediatric Intensive Care Unit, Robert Debré University Hospital, AP-HP, Paris, France), Anna Deho, MD (Paediatric Intensive Care Unit, Robert Debré University Hospital, AP-HP, Paris, France), Mehdi Oualha MD, PhD (Paediatric Intensive Care Unit, Necker-Enfants-Malades University Hospital, AP-HP, Paris, France), Zahir Amoura MD, MSc (Sorbonne Université, Inserm UMR-S 1135, Department of Immunology and Infectious disease (CIMI-Paris), Pitié-Salpêtrière Hospital, AP-HP, Paris, France), Julien Haroche MD, PhD (Sorbonne Université, Inserm UMR-S 1135, Department of Immunology and Infectious disease (CIMI-Paris), Pitié-Salpêtrière Hospital, AP-HP, Paris, France), Juliette Chommeloux MD (Medical Intensive Care Unit, Institut de Cardiologie, AP-HP, Sorbonne University, Pitié-Salpêtrière Hospital, Paris, France), Fanny Bajolle MD, PhD (Cardiopaediatric Unit, M3-C Necker-Enfants-Malades University Hospital, AP-HP, Paris, France), Stéphane Bonacorsi MD, PhD (Université de Paris, UFR de Médecine Paris Nord, 75010 Paris, France, Department of Microbiology, Robert Debré University Hospital, AP-HP, Paris, France, Infection-Antimicrobials-Modelling-Evolution IAME, INSERM, UMR-1137, Université de Paris, 75018, Paris, France), Guislaine Carcelain MD, PhD (Department of Immunology, Robert Debré University Hospital, AP-HP, Paris, France), Isabelle Kone-Paut MD (Department of Pediatric Rheumatology, Hôpital Bicêtre, AP-HP, Reference centre for Autoinflammatory diseases and amyloidosis (CEREMAIA), Le Kremlin-Bicêtre, France, Department of Immunology, Robert Debré University Hospital, AP-HP, Paris, France), Brigitte Bader-Meunier MD (Paediatric Hematology-Immunology and Rheumatology Department, Necker-Enfants-Malades University Hospital, AP-HP, Paris, France, Reference centre for Rheumatic, AutoImmune and Systemic diseases in children (RAISE), Paris, France, Laboratory of Neurogenetics and Neuroinflammation, Imagine Institute, Paris, France).

      • Contributors MP, GD, NO, AF, CG and IM designed the study. MP, GD, NO, OC, CD, UM, AF, CG and IM collected clinical data. MP, CG and IM wrote the paper. CG, AF, and IM supervised the study. All authors have read final approval of the version published.

      • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

      • Competing interests None declared.

      • Patient and public involvement Patients and/or the public were not involved in the design, or conduct, or reporting or dissemination plans of this research.

      • Provenance and peer review Commissioned; internally peer reviewed.

      Linked Articles